1978 W Winton Ave
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With more than 17,000 employees (full-time equivalent), we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 3 billion with a CORE EBITDA of CHF 987 million in H1 2022. Find out more at www.lonza.com
Rooted in the Bay Area and close to innovation in vaccines and therapeutics, our 17,200 ft2 cGMP facilities at the Hayward site provide state-of-the-art, single-use manufacturing technology to support our customers with their clinical programs. Whether our customers are developing life-saving therapies for cancer or potential treatments for COVID-19, we can support them with world-class manufacturing and process excellence. There is a chance to work with upcoming biotech and established pharmaceutical companies and to the manufacturing technology needed to produce the potential blockbuster treatments of tomorrow.
Join us and make a Meaningful Difference with us
220 articles about Lonza
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Context Therapeutics Inc. and Lonza today announced that the companies are collaborating to manufacture CTIM-76, Context’s clinical development candidate.
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
Galapagos announced that it had acquired CellPoint and AboundBio in an all-cash transaction, greatly expanding its drug portfolio.
Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and French pharmaceutical group Pierre Fabre announced that the companies have entered into a manufacturing agreement.
EV Biologics Corp announced that it has signed a Manufacturing Services Agreement with Lonza for development of stem/progenitor cell-derived nanotherapeutics and scalable biomanufacturing process.
MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing Capabilities
MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany a leading science and technology company, announced the acquisition of MAST® platform from Lonza.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
It's been a busy week so far, with new discovery facilities launched in the biotech space.
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration
Lonza to acquire and operate Codiak's Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipeline
Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
Triumvira's T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza's Cocoon ® platform at the C3i Center Inc (C3i) in Montreal
New Lonza Webinar – “An Automated Integrated QC Laboratory – MODA-EM® Software & Growth Direct® System”
On 21 September, Lonza will host a free 30-minute webinar to discuss how quality control (QC) laboratories can maximize efficiency for reduced costs and time-to-results by combining Lonza’s MODA-EM® Software and the Growth Direct® System from Rapid Micro Biosystems.
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it has entered into an additional agreement with Lonza to support drug substance manufacturing for its global supply chain.
Work-at-home arrangements created to respond to the COVID-19 pandemic have forced numerous companies in most sectors to reevaluate their work deals. This has also resulted in rethinking site locations and real estate needs. Here’s a look.
Lonza has been in the process of separating LSI into a standalone unit since 2019.
The new agreement will provide Lonza with access to Arbor’s gene editing technology Quote from David Cheng, CEO of Arbor: “Arbor's differentiated gene editing technologies allow Lonza to manufacture the next generation of therapeutics. Arbor is committed to seeking and working with partners in this field to build an ecosystem for the research, development and manufacturing of biological and cellular therapies.”
Lonza and Be The Match BioTherapies Partner to Expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network
Be The Match BioTherapies as a preferred partner to provide consistent access to high-quality, healthy donor tissue and cell and gene therapy (CGT) supply chain support
Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab
In an effort to change the course of this pandemic, advancing lead COVID-19 therapeutics requires matched supply chain efforts and expertise to meet the continued and urgent patient needs.
IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing
- Lonza to utilize of IsoPlexis' IsoLight® automated proteomics platform - IsoLight® to be used for functional quality analytics for cell therapy products produced on Lonza's Cocoon® Platform, an automated cell manufacturing platform [20-August-2020] BASEL, Switzerland and BRANFORD, Conn. , Aug. 20, 2020 /PRNewswire/ -- Quote from Matthew Hewitt , Hea
Anthos Therapeutics Partners with Lonza to Develop and Manufacture Abelacimab (MAA868), a Unique Dual Factor XI / XIa inhibitor
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza Ltd. announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine against the novel coronavirus and additional Moderna products in the future.